This study seeks to understand the neural, cognitive and behavioral effects of low doses of psilocybin administered in the form of dried mushroom material (0.5 g of Psilocybe cubensis) consumed in natural settings following a placebo-controlled double-blind experimental design.
Sub-threshold doses of serotonergic psychedelics are frequently consumed as cognitive enhancers, and due to their purported positive effects on mood, energy and creativity ("microdosing"). The acute and short-term effects of psilocybin (the psychoactive compound of Psilocybe cubensis mushrooms) on several variables will be investigated, comprising spontaneous and evoked electrophysiological brain activity, perception and cognitive function (cognitive flexibility, attention, inhibitory control, conscious access, visual perception), creativity (problem solving, divergent and convergent thinking), behavior (actigraphy and sleep patterns, natural language production) and several domains related to well-being and mental health of the participants. This study is simultaneously naturalistic (i.e. recruited subjects are intrinsically motivated to microdose, as they have decided to embark in a microdosing protocol) and controlled by expectations, following a double-blind placebo-controlled design. Participants will microdose according to the following schedule: Two sessions (0.5 g dried Psilocybin mushrooms vs. dried edible mushroom material without psychoactive effects as a placebo condition) will be conducted. A third party will be in charge of generating their active dose and placebo capsules, and they will also implement a blinding procedure. Each session will span one week of measurements. Subjects will be given a smartwatch to monitor activity and sleeping patterns at the beginning of the week. At days 3 and 5, subjects will take capsules with active mushroom material or placebo, and then several variables will be recorded. Experiments will be conducted in a setting that is natural and comfortable for the participants, e.g. their homes. The main outcome measures consist of resting state activity recorded with EEG, evoked response potentials and performance during cognitive tasks, behavioral variables obtained with actigraphy and automated sleep scoring, natural language analysis, and several measurs self-reported via standarized questionnaires. After completion, this study will provide direct evidence concerning the efficacy of microdosing for cognitive enhancement under natural conditions, i.e. those most frequently used by individuals who microdose, as well as provide information concerning the potential underlying neurobiological mechanisms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
34
0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
0.5 g dried edible non-psychoactive mushroom material.
Instituto de Fisica de Buenos Aires (IFIBA)
Buenos Aires, Argentina
Resting state oscillations measured with EEG
Our goal is to study changes in spectral content before and during the acute effects with the purpose of comparing changes with those observed under higher doses of psilocybin.
Time frame: 1 week
Attention
Measured performance in the attentional blink paradigm
Time frame: 1 week
Inhibitory control
Measured using the go/no go experimental paradigm
Time frame: 1 week
Conscious access
Measured using the backward masking paradigm
Time frame: 1 week
Visual perception
Measured using the binocular rivalry paradigm
Time frame: 1 week
Physical activity
Measured using wrist actigraphy using a smartwach
Time frame: 1 week
Divergent thinking
Measured using the Alternative Uses Task (AUT)
Time frame: 1 week
Attention
Measured using the hiearchical mismatch negativity paradigm combined with EEG
Time frame: 1 week
Cognitive flexibility
Measured using the stroop task
Time frame: 1 week
Convergent thinking
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Measured using the Remote Associations Task (RAT)
Time frame: 1 week
Convergent thinking
Measured using the Wallach-Kogan test (WK)
Time frame: 1 week
Effect positive/negative affect and well-being
Measured using the Positive and Negative Affect Schedule (PANAS)
Time frame: 1 week
Effects on anxiety
Measured using State Trait Anxiety Inventory (STAI)
Time frame: 1 week
Effects on personality
Measured using the Big Five inventory (BFI)
Time frame: 1 week
Concentration of psilocybin in the dried material
To be measured using high performance liquid chromatography
Time frame: 1 week